Summary

The global nucleic acid isolation and purification market, is expected to reach USD 15.44 billion by 2032 from USD 7.21 billion in 2024, growing at a substantial CAGR of 10.6% in the forecast period of 2025 to 2032.
Market Segmentation:
Global Nucleic Acid Isolation and Purification Market, By Product (Instruments, Kits, and Reagents), Method (Magnetic Bead-Based Isolation and Purification, Column -Based Isolation and Purification, Reagent-Based Isolation and Purification, and Others), Type (Next Generation Sequencing (NGS), Genomic DNA Isolation and Purification, Total RNA Isolation and Purification, PCR Clean-Up, Plasmid DNA Isolation and Purification, Messenger RNA Isolation and Purification, Circulating Nucleic Acid Isolation and Purification, MicroRNA Isolation and Purification and Others), Application (Diagnostics, Drug Discovery and Development, Personalized Medicine, Agriculture and Animal Research, and Others), Sample Type (FFPE Samples, Blood Cells, Bacteria, Yeast, and Plants, Cell-Free Samples, Cultured Cells, Mammalian Cells, Brain and Kidney Tissue, and Others), End User (Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Contract Development and manufacturing Organization (CDMO), Academic/Research Institutes, and Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Russia, Turkey, Belgium, Netherlands, Denmark, Poland, Sweden, Norway, Finland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Indonesia, Thailand, Malaysia, Philippines, New Zealand, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Qatar, Egypt, Kuwait, Bahrain, Oman, and Rest of Middle East and Africa) - Industry Trends & Forecast To 2032
Overview of the Global Nucleic Acid Isolation and Purification Market Dynamics

Driver

• Increasing Prevalence Of Genetic Disorders

Restraint

• Risks Associated With Sample Contamination

Opportunity

• Rise In Technological Advancements and Automation

Market Players:

The key market players for global nucleic acid isolation and purification market are listed below:

• Merck KGaA
• Cytiva (Danaher Corporation)
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Illumina Inc.
• PerkinElmer
• Meridian Bioscience, Inc.
• QIAGEN
• Takara Bio Inc.
• MACHEREY-NAGEL GmbH & Co. KG
• Lepu Medical Technology (Beijing) Co.,Ltd.
• Promega Corporation
• New England Biolabs
• KURABO INDUSTRIES LTD.
• Omega Bio-tek, Inc.
• Zymo Research Corporation
• Analytik Jena GmbH+Co. KG
• LGC Biosearch Technologies
• Daan Gene Co., Ltd.
• MagGenome Technologies Pvt. Ltd.
• TIANGEN BIOTECH (BEIJING) CO.,LTD.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 99
1.1 OBJECTIVES OF THE STUDY 99
1.2 MARKET DEFINITION 99
1.3 OVERVIEW OF GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 99
1.4 MARKETS COVERED 103
2 MARKET SEGMENTATION 107
2.1 MARKETS COVERED 107
2.2 GEOGRAPHICAL SCOPE 108
2.3 YEARS CONSIDERED FOR THE STUDY 109
2.4 CURRENCY AND PRICING 109
2.5 DBMR TRIPOD DATA VALIDATION MODEL 110
2.6 MULTIVARIATE MODELLING 113
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 114
2.8 DBMR MARKET POSITION GRID 115
2.9 VENDOR SHARE ANALYSIS 116
2.10 MARKET END USER COVERAGE GRID 117
2.11 SECONDARY SOURCES 118
2.12 ASSUMPTIONS 118
3 EXECUTIVE SUMMARY 119
4 PREMIUM INSIGHT 127
4.1 PORTER’S FIVE FORCES 129
4.2 PESTEL ANALYSIS 130
4.3 DEFINITION AND IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 131
5 GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: REGULATIONS 137
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION 137
5.2 NORTH AMERICA REGULATORY SCENARIO 142
5.3 EUROPE REGULATORY SCENARIO 147
5.4 REGULATORY SUBMISSIONS 149
6 MARKET OVERVIEW 160
6.1 DRIVERS 162
6.1.1 INCREASING PREVALENCE OF GENETIC DISORDERS 162
6.1.2 INCREASING DEMAND FOR DIAGNOSTIC TESTING 164
6.1.3 RISING INVESTMENT IN GENOMICS RESEARCH 165
6.1.4 INCREASE IN LAUNCH OF DIAGNOSTIC PRODUCTS 166
6.2 RESTRAINTS 167
6.2.1 RISKS ASSOCIATED WITH SAMPLE CONTAMINATION 167
6.2.2 HIGH COST OF EQUIPMENT AND REAGENTS 168
6.3 OPPORTUNITIES 169
6.3.1 RISE IN TECHNOLOGICAL ADVANCEMENTS AND AUTOMATION 169
6.3.2 INCREASING ADOPTION OF NEXT-GENERATION SEQUENCING (NGS) 170
6.3.3 GROWING APPLICATIONS OF LIQUID BIOPSY IN NON-INVASIVE DIAGNOSTICS 171
6.4 CHALLENGES 173
6.4.1 TECHNICAL DIFFICULTIES IN NUCLEIC ACID ISOLATION ACROSS DIFFERENT SAMPLE TYPES 173
6.4.2 ENVIRONMENTAL AND SUSTAINABILITY CONCERNS 174
7 GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE 175
7.1 OVERVIEW 176
7.2 NEXT GENERATION SEQUENCING (NGS) 180
7.3 GENOMIC DNA ISOLATION AND PURIFICATION 180
7.4 TOTAL RNA ISOLATION AND PURIFICATION 181
7.5 PCR CLEAN-UP 181
7.6 PLASMID DNA ISOLATION AND PURIFICATION 182
7.7 MESSENGER RNA ISOLATION AND PURIFICATION 182
7.8 CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION 183
7.9 MICRORNA ISOLATION AND PURIFICATION 183
7.10 OTHERS 184
8 GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT 185
8.1 OVERVIEW 186
8.2 INSTRUMENTS 189
8.2.1 HOMOGENIZER 190
8.2.2 SPECTROPHOTOMETERS 190
8.2.3 FLUOROMETERS 190
8.2.4 OTHERS 190
8.2.4.1 BENCHTOP 191
8.2.4.2 STANDALONE 191
8.2.4.2.1 AUTOMATED 191
8.2.4.2.2 MANUAL 191
8.3 KITS 191
8.3.1 DNA ISOLATION & PURIFICATION KITS 192
8.3.2 RNA ISOLATION & PURIFICATION KITS 192
8.3.3 VIRAL NUCLEIC ACID ISOLATION KITS 192
8.3.4 PLASMID PURIFICATION KIT 192
8.3.5 PCR AND GEL KIT 192
8.3.6 OTHERS 193
8.3.6.1 MAGNETIC BEAD-BASED KIT 193
8.3.6.2 COLUMN-BASED KIT 193
8.3.6.3 REAGENT-BASED KIT 193
8.3.6.3.1 VIRAL/PATHOGEN NUCLEIC ACID ISOLATION KIT 194
8.3.6.3.2 PLANT DNA ISOLATION KIT 194
8.3.6.3.3 CELL-FREE TOTAL NUCLEIC ACID KIT 194
8.3.6.3.4 CELL-FREE DNA ISOLATION KIT 194
8.3.7 GENOMIC DNA PURIFICATION KIT 196
8.3.8 VIRAL RNA/DNA PURIFICATION KIT 196
8.3.9 PLANT DNA PURIFICATION KIT 196
8.3.10 MICROBIOME DNA PURIFICATION KIT 196
8.3.11 OTHERS 196
8.3.12 MAGNETIC BEAD-BASED KIT 196
8.3.13 COLUMN-BASED KIT 196
8.3.14 REAGENT-BASED KIT 196
8.3.15 VIRAL/PATHOGEN NUCLEIC ACID ISOLATION KIT 198
8.3.16 MRNA PURIFICATION KIT 198
8.3.17 PLANT RNA ISOLATION KIT 198
8.3.18 CELL-FREE NUCLEIC ACID ISOLATION KIT 198
8.3.19 OTHERS 198
8.3.20 RNA ISOLATION KIT 199
8.3.21 MI RNA ISOLATION KIT 199
8.3.22 VIRAL RNA/DNA KIT 199
8.3.23 MAGNETIC BEAD-BASED KITS 200
8.3.24 VIRAL SPIN-COLUMN KITS 200
8.4 REAGENTS 200
8.4.1 DNA ISOLATION REAGENT 201
8.4.2 RNA ISOLATION REAGENT 201
8.4.3 OTHERS 201
9 GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE 202
9.1 OVERVIEW 203
9.2 FFPE SAMPLES 206
9.3 BLOOD CELLS 206
9.4 BACTERIA, YEAST, AND PLANTS 207
9.5 CELL-FREE SAMPLES 207
9.6 CULTURED CELLS 208
9.7 MAMMALIAN CELLS 208
9.8 BRAIN AND KIDNEY TISSUE 209
9.9 OTHERS 209
10 GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD 210
10.1 OVERVIEW 211
10.2 MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION 214
10.3 COLUMN -BASED ISOLATION AND PURIFICATION 214
10.4 REAGENT-BASED ISOLATION AND PURIFICATION 215
10.5 OTHERS 215
11 GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION 216
11.1 OVERVIEW 217
11.2 DIAGNOSTICS 220
11.2.1 INSTRUMENTS 220
11.2.2 KITS 220
11.2.3 REAGENTS 220
11.3 DRUG DISCOVERY AND DEVELOPMENT 221
11.3.1 INSTRUMENTS 221
11.3.2 KITS 221
11.3.3 REAGENTS 221
11.4 PERSONALIZED MEDICINE 222
11.4.1 INSTRUMENTS 222
11.4.2 KITS 222
11.4.3 REAGENTS 222
11.5 AGRICULTURE AND ANIMAL RESEARCH 223
11.5.1 INSTRUMENTS 223
11.5.2 KITS 223
11.5.3 REAGENTS 223
11.6 OTHERS 224
12 GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER 225
12.1 OVERVIEW 226
12.2 HOSPITALS AND DIAGNOSTIC CENTERS 229
12.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 229
12.4 CONTRACT RESEARCH ORGANIZATIONS 230
12.5 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) 230
12.6 ACADEMIC/RESEARCH INSTITUTES 231
12.7 OTHERS 231
13 GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY REGION 232
13.1 OVERVIEW 233
13.2 NORTH AMERICA 236
13.2.1 U.S. 253
13.2.2 CANADA 269
13.2.3 MEXICO 284
13.3 EUROPE 299
13.3.1 GERMANY 315
13.3.2 U.K. 328
13.3.3 FRANCE 341
13.3.4 ITALY 354
13.3.5 SPAIN 367
13.3.6 SWITZERLAND 380
13.3.7 RUSSIA 393
13.3.8 TURKEY 406
13.3.9 BELGIUM 419
13.3.10 NETHERLANDS 432
13.3.11 DENMARK 445
13.3.12 POLAND 458
13.3.13 SWEDEN 471
13.3.14 NORWAY 483
13.3.15 FINLAND 495
13.3.16 REST OF EUROPE 507
13.4 ASIA-PACIFIC 508
13.4.1 CHINA 524
13.4.2 JAPAN 537
13.4.3 INDIA 549
13.4.4 SOUTH KOREA 561
13.4.5 AUSTRALIA 573
13.4.6 SINGAPORE 585
13.4.7 INDONESIA 597
13.4.8 THAILAND 609
13.4.9 MALAYSIA 623
13.4.10 PHILIPPINES 636
13.4.11 NEW ZEALAND 649
13.4.12 VIETNAM 662
13.4.13 TAIWAN 675
13.4.14 REST OF ASIA-PACIFIC 688
13.5 MIDDLE EAST AND AFRICA 689
13.5.1 SOUTH AFRICA 702
13.5.2 SAUDI ARABIA 714
13.5.3 U.A.E. 726
13.5.4 QATAR 738
13.5.5 EGYPT 750
13.5.6 KUWAIT 762
13.5.7 BAHRAIN 774
13.5.8 OMAN 786
13.5.9 REST OF MIDDLE EAST AND AFRICA 798
13.6 SOUTH AMERICA 799
13.6.1 BRAZIL 814
13.6.2 ARGENTINA 829
13.6.3 REST OF SOUTH AMERICA 844
14 GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: COMPANY LANDSCAPE 845
14.1 COMPANY SHARE ANALYSIS: GLOBAL 845
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 846
14.3 COMPANY SHARE ANALYSIS: EUROPE 847
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 848
15 SWOT ANALYSIS 849
16 COMPANY PROFILE 850
16.1 MERCK KGAA 850
16.1.1 COMPANY SNAPSHOT 850
16.1.2 REVENUE ANALYSIS 850
16.1.3 COMPANY SHARE ANALYSIS 851
16.1.4 PRODUCT PORTFOLIO 851
16.1.5 RECENT DEVELOPMENT 851
16.2 CYTIVA (DANAHER CORPORATION) 852
16.2.1 COMPANY SNAPSHOT 852
16.2.2 REVENUE ANALYSIS 852
16.2.3 COMPANY SHARE ANALYSIS 853
16.2.4 PRODUCT PORTFOLIO 853
16.2.5 RECENT DEVELOPMENTS 854
16.3 AGILENT TECHNOLOGIES, INC. 856
16.3.1 COMPANY SNAPSHOT 856
16.3.2 REVENUE ANALYSIS 856
16.3.3 COMPANY SHARE ANALYSIS 857
16.3.4 PRODUCT PORTFOLIO 857
16.3.5 RECENT DEVELOPMENT 860
16.4 BIO-RAD LABORATORIES, INC. 861
16.4.1 COMPANY SNAPSHOT 861
16.4.2 REVENUE ANALYSIS 861
16.4.3 COMPANY SHARE ANALYSIS 862
16.4.4 PRODUCT PORTFOLIO 862
16.4.5 RECENT DEVELOPMENT 863
16.5 F. HOFFMANN-LA ROCHE LTD 864
16.5.1 COMPANY SNAPSHOT 864
16.5.2 REVENUE ANALYSIS 864
16.5.3 COMPANY SHARE ANALYSIS 865
16.5.4 PRODUCT PORTFOLIO 865
16.5.5 RECENT DEVELOPMENT 865
16.6 ANALYTIK JENA GMBH+CO. KG 866
16.6.1 COMPANY SNAPSHOT 866
16.6.2 PRODUCT PORTFOLIO 866
16.6.3 RECENT DEVELOPMENT 866
16.7 AUTOGEN, INC. 868
16.7.1 COMPANY SNAPSHOT 868
16.7.2 PRODUCT PORTFOLIO 868
16.7.3 RECENT DEVELOPMENT 871
16.8 DAAN GENE CO., LTD. 872
16.8.1 COMPANY SNAPSHOT 872
16.8.2 PRODUCT PORTFOLIO 872
16.8.3 RECENT DEVELOPMENT 874
16.9 HIMEDIA LABORATORIES 875
16.9.1 COMPANY SNAPSHOT 875
16.9.2 PRODUCT PORTFOLIO 875
16.9.3 RECENT DEVELOPMENT 876
16.10 ILLUMINA, INC. 877
16.10.1 COMPANY SNAPSHOT 877
16.10.2 REVENUE ANALYSIS 877
16.10.3 PRODUCT PORTFOLIO 878
16.10.4 RECENT DEVELOPMENT 878
16.11 KURABO INDUSTRIES LTD. 879
16.11.1 COMPANY SNAPSHOT 879
16.11.2 REVENUE ANALYSIS 879
16.11.3 PRODUCT PORTFOLIO 880
16.11.4 RECENT DEVELOPMENT 882
16.12 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD. 883
16.12.1 COMPANY SNAPSHOT 883
16.12.2 REVENUE ANALYSIS 883
16.12.3 PRODUCT PORTFOLIO 884
16.12.4 RECENT DEVELOPMENT 885
16.13 LGC BIOSEARCH TECHNOLOGIES 886
16.13.1 COMPANY SNAPSHOT 886
16.13.2 PRODUCT PORTFOLIO 886
16.13.3 RECENT DEVELOPMENTS 887
16.14 MACHEREY-NAGEL GMBH & CO. KG 888
16.14.1 COMPANY SNAPSHOT 888
16.14.2 PRODUCT PORTFOLIO 888
16.14.3 RECENT DEVELOPMENT 888
16.15 MAGGENOME TECHNOLOGIES PVT. LTD. 889
16.15.1 COMPANY SNAPSHOT 889
16.15.2 PRODUCT PORTFOLIO 889
16.15.3 RECENT DEVELOPMENT 893
16.16 MEDOX BIOTECH INDIA PVT. LTD. 894
16.16.1 COMPANY SNAPSHOT 894
16.16.2 PRODUCT PORTFOLIO 894
16.16.3 RECENT DEVELOPMENT 895
16.17 MERIDIAN BIOSCIENCE, INC. 896
16.17.1 COMPANY SNAPSHOT 896
16.17.2 PRODUCT PORTFOLIO 896
16.17.3 RECENT DEVELOPMENT 896
16.18 NEW ENGLAND BIOLABS 897
16.18.1 COMPANY SNAPSHOT 897
16.18.2 PRODUCT PORTFOLIO 897
16.18.3 RECENT DEVELOPMENT 898
16.19 NORGEN BIOTEK CORP. 899
16.19.1 COMPANY SNAPSHOT 899
16.19.2 PRODUCT PORTFOLIO 899
16.19.3 RECENT DEVELOPMENT 900
16.20 OMEGA BIO-TEK, INC. 901
16.20.1 COMPANY SNAPSHOT 901
16.20.2 PRODUCT PORTFOLIO 901
16.20.3 RECENT DEVELOPMENT 903
16.21 PCR BIOSYSTEMS 904
16.21.1 COMPANY SNAPSHOT 904
16.21.2 PRODUCT PORTFOLIO 904
16.21.3 RECENT DEVELOPMENT 904
16.22 PERKINELMER 905
16.22.1 COMPANY SNAPSHOT 905
16.22.2 REVENUE ANALYSIS 905
16.22.3 PRODUCT PORTFOLIO 906
16.22.4 RECENT DEVELOPMENT 906
16.23 PROMEGA CORPORATION 907
16.23.1 COMPANY SNAPSHOT 907
16.23.2 PRODUCT PORTFOLIO 907
16.23.3 RECENT DEVELOPMENT 907
16.24 QIAGEN 908
16.24.1 COMPANY SNAPSHOT 908
16.24.2 REVENUE ANALYSIS 908
16.24.3 PRODUCT PORTFOLIO 909
16.24.4 RECENT DEVELOPMENTS/NEWS 910
16.25 SAGE SCIENCE, INC. 911
16.25.1 COMPANY SNAPSHOT 911
16.25.2 PRODUCT PORTFOLIO 911
16.25.3 RECENT DEVELOPMENTS 911
16.26 TAKARA BIO INC. 913
16.26.1 COMPANY SNAPSHOT 913
16.26.2 REVENUE ANALYSIS 913
16.26.3 PRODUCT PORTFOLIO 914
16.26.4 RECENT DEVELOPMENTS 914
16.27 THERMO FISHER SCIENTIFIC INC. 915
16.27.1 COMPANY SNAPSHOT 915
16.27.2 REVENUE ANALYSIS 915
16.27.3 PRODUCT PORTFOLIO 916
16.27.4 RECENT DEVELOPMENT 919
16.28 TIANGEN BIOTECH (BEIJING) CO.,LTD. 921
16.28.1 COMPANY SNAPSHOT 921
16.28.2 PRODUCT PORTFOLIO 921
16.28.3 RECENT DEVELOPMENT 921
16.29 XI'AN TIANLONG SCIENCE AND TECHNOLOGY CO., LTD 922
16.29.1 COMPANY SNAPSHOT 922
16.29.2 PRODUCT PORTFOLIO 922
16.29.3 RECENT DEVELOPMENT 923
16.30 ZYMO RESEARCH CORPORATION 924
16.30.1 COMPANY SNAPSHOT 924
16.30.2 PRODUCT PORTFOLIO 924
16.30.3 RECENT DEVELOPMENT 925
17 QUESTIONNAIRE 926
18 RELATED REPORTS 930